Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and Anheuser (English)
- New search for: Tandstad, T.
- New search for: Cohn-Cedermark, G.
- New search for: Tandstad, T.
- New search for: Cohn-Cedermark, G.
In:
ANNALS OF ONCOLOGY
;
27
, 9
;
1809-1809
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and Anheuser
-
Contributors:Tandstad, T. ( author ) / Cohn-Cedermark, G. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27, 9 ; 1809-1809
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:1 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27, Issue 9
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1655
-
New goalsSoria, J. C. et al. | 2016
- 1656
-
Saving the best treatment for last?Coleman, R. L. / Monk, B. J. et al. | 2016
- 1658
-
PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?Al-Ahmadie, H. et al. | 2016
- 1660
-
Communication in oncology: now we train - but how well?†Stiefel, F. / Bourquin, C. et al. | 2016
- 1664
-
Cervical esophageal cancer: a gap in cancer knowledgeHoeben, A. / Polak, J. / Van De Voorde, L. / Hoebers, F. / Grabsch, H. I. / de Vos-Geelen, J. et al. | 2016
- 1675
-
The promise of immunotherapy in head and neck squamous cell carcinomaEconomopoulou, P. / Agelaki, S. / Perisanidis, C. / Giotakis, E. I. / Psyrri, A. et al. | 2016
- 1685
-
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveShenoy, N. / Pagliaro, L. et al. | 2016
- 1696
-
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyClancy, A. A. / Spaans, J. N. / Weberpals, J. I. et al. | 2016
- 1706
-
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approachesUdager, A. M. / Liu, T. Y. / Skala, S. L. / Magers, M. J. / McDaniel, A. S. / Spratt, D. E. / Feng, F. Y. / Siddiqui, J. / Cao, X. / Fields, K. L. et al. | 2016
- 1712
-
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancerLacouture, M. E. / Keefe, D. M. / Sonis, S. / Jatoi, A. / Gernhardt, D. / Wang, T. / Doherty, J. P. / Giri, N. / Nadanaciva, S. / O'Connell, J. et al. | 2016
- 1719
-
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)Jerusalem, G. / Mariani, G. / Ciruelos, E. M. / Martin, M. / Tjan-Heijnen, V. C. / Neven, P. / Gavila, J. G. / Michelotti, A. / Montemurro, F. / Generali, D. et al. | 2016
- 1725
-
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyDelaloge, S. / Pérol, D. / Courtinard, C. / Brain, E. / Asselain, B. / Bachelot, T. / Debled, M. / Dieras, V. / Campone, M. / Levy, C. et al. | 2016
- 1733
-
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trialTrillsch, F. / Mahner, S. / Hilpert, F. / Davies, L. / García-Martínez, E. / Kristensen, G. / Savarese, A. / Vuylsteke, P. / Los, M. / Zagouri, F. et al. | 2016
- 1740
-
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)Volgger, B. M. / Windbichler, G. H. / Zeimet, A. G. / Graf, A. H. / Bogner, G. / Angleitner-Boubenizek, L. / Rohde, M. / Denison, U. / Sliutz, G. / Fuith, L. C. et al. | 2016
- 1746
-
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupModest, D. P. / Ricard, I. / Heinemann, V. / Hegewisch-Becker, S. / Schmiegel, W. / Porschen, R. / Stintzing, S. / Graeven, U. / Arnold, D. / von Weikersthal, L. F. et al. | 2016
- 1754
-
Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trialKrebber, A. M. / Jansen, F. / Witte, B. I. / Cuijpers, P. / de Bree, R. / Becker-Commissaris, A. / Smit, E. F. / van Straten, A. / Eeckhout, A. M. / Beekman, A. T. et al. | 2016
- 1761
-
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective studyVardy, J. L. / Dhillon, H. M. / Pond, G. R. / Renton, C. / Dodd, A. / Zhang, H. / Clarke, S. J. / Tannock, I. F. et al. | 2016
- 1768
-
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countriesKleijnen, S. / Lipska, I. / Leonardo Alves, T. / Meijboom, K. / Elsada, A. / Vervölgyi, V. / d'Andon, A. / Timoney, A. / Leufkens, H. G. / De Boer, A. et al. | 2016
- 1776
-
To be in pain (or not): a computer enables outpatients to inform their physicianOldenmenger, W. H. / Witkamp, F. E. / Bromberg, J. E. / Jongen, J. L. / Lieverse, P. J. / Huygen, F. J. / Baan, M. A. / van Zuylen, L. / van der Rijt, C. C. et al. | 2016
- 1782
-
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma†Simonelli, M. / Zucali, P. / Santoro, A. / Thomas, M. B. / de Braud, F. G. / Borghaei, H. / Berlin, J. / Denlinger, C. S. / Noberasco, C. / Rimassa, L. et al. | 2016
- 1788
-
Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcomeRuiz-Pinto, S. / Pita, G. / Patiño-García, A. / García-Miguel, P. / Alonso, J. / Pérez-Martínez, A. / Sastre, A. / Gómez-Mariano, G. / Lissat, A. / Scotlandi, K. et al. | 2016
- 1794
-
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyBen-Ami, E. / Barysauskas, C. M. / von Mehren, M. / Heinrich, M. C. / Corless, C. L. / Butrynski, J. E. / Morgan, J. A. / Wagner, A. J. / Choy, E. / Yap, J. T. et al. | 2016
- 1799
-
Inclusion of elderly patients in oncology clinical trialsLe Saux, O. / Falandry, C. / Gan, H. K. / You, B. / Freyer, G. / Péron, J. et al. | 2016
- 1805
-
Oncolytic immunotherapy: an emerging new modality for the treatment of cancerCoffin, R. S. et al. | 2016
- 1809
-
Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and AnheuserTandstad, T. / Cohn-Cedermark, G. et al. | 2016
- 1810
-
Reply to ‘Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients’ by C. Cremolini et al.Luo, H. Y. / Xu, R. H. et al. | 2016
- 1810
-
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patientsCremolini, C. / Moretto, R. / Masi, G. / Falcone, A. et al. | 2016
- 1811
-
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL)Tan, D. / Diong, C. P. / Loh, Y. / Goh, Y. T. et al. | 2016
- 1812
-
Challenging the soaring price of cancer medicines: a call for equity and transparencyGonçalves, A. / Maraninchi, D. / Vernant, J. P. et al. | 2016
- 1813
-
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumabHeine, A. / Kristiansen, G. / Schild, H. H. / Brossart, P. et al. | 2016